<DOC>
	<DOC>NCT01296243</DOC>
	<brief_summary>Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.</brief_summary>
	<brief_title>Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Key At least 18 years of age Histologically confirmed prostate cancer, currently with progressive disease Evidence of metastatic disease Castrate level of testosterone (&lt; 50 ng/dL) Eastern Cooperative Oncology Group performance status 0 or 1 Chemotherapyna√Øve Adequate bone marrow, hepatic, and renal function Ability to swallow an oral soliddosage form of medication Key History or presence of brain metastasis or leptomeningeal disease Operable cancer Uncontrolled diarrhea Uncontrolled nausea or vomiting Known malabsorptive disorder Currently active second malignancy other than nonmelanoma skin cancers Human immunodeficiency virus (HIV) infection based on history of positive serology Significant medical disease other than cancer Presence of neuropathy &gt; Grade 2 (National Cancer Institute Common Toxicity Criteria [NCI CTC]; v4.0) Need for other anticancer treatment Need to continue any regularlytaken medication that is a potent inhibitor or inducer of the CYP3A pathway or Pglycoprotein activity Less than 2 weeks since use of a medication or ingestion of an agent, beverage, or food that is a potent inhibitor or inducer of the CYP3A pathway or Pglycoprotein activity Less than 4 weeks since use of another investigational agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Castration-resistant prostate cancer</keyword>
	<keyword>Tesetaxel</keyword>
	<keyword>Taxanes</keyword>
	<keyword>Chemotherapy-naive</keyword>
	<keyword>Chemotherapy-exposed</keyword>
	<keyword>Progressive, metastatic castration-resistant prostate cancer</keyword>
</DOC>